BUSINESS WIRE: ASCO-GI: Overall Survival With Erbitux Is Significantly Improved in Patients With KRAS Wild-Type Tumors … (vwd.de)
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
See the original post here:
BUSINESS WIRE: ASCO-GI: Overall Survival With Erbitux Is Significantly Improved in Patients With KRAS Wild-Type Tumors … (vwd.de)
